Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid antagonist reversal of fentanyl- and sufentanil-induced respiratory depression
NL-OMON59242Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of naloxone, nalmefene, fentanyl and sufentanil in opioid-induced respiratory depression (OIRD) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Minute ventilation with PK/PD modeling. Started Jun 2022; status: completed.
02
Drugs
naloxonenalmefenefentanylsufentanil
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NL-OMON59242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59242.